Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial

被引：0
|
作者：
Kasper, S. [1 ]
Meiler, J. [1 ]
Knipp, H. [2 ]
Hoehler, T. [3 ]
Reimer, P. [4 ]
Steinmetz, T. [5 ]
Berger, W. [6 ]
Linden, G. [1 ]
Ting, S. [7 ]
Markus, P. [8 ]
Paul, A. [9 ]
Dechene, A. [10 ]
Kostbade, K. [1 ]
Schuler, M. [1 ]
Trarbach, T. [1 ]
机构：
[1] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany
[2] Alfried Krupp von Bohlen & Halbach Hosp, Dept Med 1, Essen, Germany
[3] Prosper Hosp, Dept Med 1, Recklinghausen, Germany
[4] Hosp Essen Werden, Dept Hematol & Med Oncol, Essen, Germany
[5] Grp Practice Hematol Oncol, Cologne, Germany
[6] Catholic Hosp, Dept Hematol & Med Oncol, Essen, Germany
[7] Univ Hosp Essen, West German Canc Ctr, Inst Pathol, Essen, Germany
[8] Elisabeth Hosp, Dept Gen Visceral & Trauma Surg, Essen, Germany
[9] Univ Hosp Essen, West German Canc Ctr, Dept Gen Visceral & Transplantat Surg, Essen, Germany
[10] Univ Hosp Essen, West German Canc Ctr, Dept Gastroenterol & Hepatol, Essen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V328
引用
收藏
页码：99 / 100
页数：2
相关论文
共 50 条
  • [21] Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study)
    Kim, Ho Min
    Soda, Hitoshi
    Hazama, Shoichi
    Takahashi, Takao
    Nagata, Naoki
    Kotaka, Masahito
    Kono, Emiko
    Terada, Itsurou
    Fukunaga, Mutsumi
    Oba, Koji
    Hasegawa, Junichi
    Sakamoto, Junichi
    Mishima, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [22] Cost-effectiveness of cetuximab, bevacizumab, and panitumumab in first-line treatment of metastatic colorectal cancer (mCRC) for patients with KRAS wild-type (wt) tumors in the United Kingdom
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC).
    Gibbs, Peter
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget Anne
    Strickland, Andrew
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan Thomas
    Boucher, Eveline
    Tichler, Thomas E.
    Gebski, Val
    Van Buskirk, Mark
    Van Hazel, Guy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [24] CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.
    Xu, Jianming
    Cao, Bangwei
    Gu, Kangsheng
    Bai, Yuxian
    Li, Wei
    Zhang, Jingdong
    Liu, Caigang
    Niu, Zuoxing
    Zhang, Liangming
    Zhong, Haijun
    Luo, Suxia
    Zhou, Jian-Wei
    Liu, Tianshu
    Gu, Yanhong
    Lin, Jingguan
    Deng, Yanhong
    Chen, Chuangqi
    Li, Yunfeng
    Yang, Xiuli
    Li, Bihui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC)
    Hamaguchi, T.
    Yoshino, T.
    Ohtsu, A.
    Yamazaki, K.
    Shimada, Y.
    Kato, K.
    Yasui, H.
    Boku, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 340 - 340
  • [26] Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
    Lang, Istvan
    Koehne, Claus-Henning
    Folprecht, Gunnar
    Rougier, Philippe
    Curran, Desmond
    Hitre, Erika
    Sartorius, Ute
    Griebsch, Ingolf
    Van Cutsem, Eric
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) : 439 - 448
  • [27] Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer
    Giuliani, Jacopo
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1674 - 1676
  • [28] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Ohta, Katsuya
    Ikenaga, Masakazu
    Uemura, Mamoru
    Sakata, Kazuya
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 216 - 216
  • [29] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Uemura, Mamoru
    Kim, Ho Min
    Hata, Tsuyoshi
    Sakata, Kazuya
    Okuyama, Masaki
    Takemoto, Hiroyoshi
    Fujii, Hitoshi
    Fukuzaki, Takayuki
    Morita, Tetsushi
    Hata, Taishi
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Maski
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) : 375 - 379
  • [30] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
    Lawrence, D.
    Maschio, M.
    Yunger, S.
    Easaw, J.
    Aucoin, N.
    Weinstein, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
12345